Celldex Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1983-01-01

Employees: 160

Market Cap: $2.5B

Website: http://www.celldex.com

Clinical Trials

A Study of CDX-0159 in Patients With Prurigo Nodularis

Phase 1

Completed

Conditions: Prurigo Nodularis

Interventions: Biological: CDX-0159
Drug: Normal saline

First Posted Date: 2021-06-30

Last Posted Date: 2023-08-14

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 24

Registration Number: NCT04944862

Locations: 🇺🇸
Markowitz Medical/Optiskin, New York, New York, United States
🇺🇸
Revival Research Institute, LLC, Troy, Michigan, United States
🇵🇱
MT Medic Specjalistyczna Praktyka Lekarska, Krosno, Poland

and more 14 locations

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria

Phase 1

Completed

Conditions: Cold Urticaria
Cold Contact Urticaria
Symptomatic Dermatographism
Symptomatic Dermographism
Cholinergic Urticaria

Interventions: Drug: CDX-0159

First Posted Date: 2020-09-16

Last Posted Date: 2023-05-17

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 41

Registration Number: NCT04548869

Locations: 🇩🇪
Charite University, Berlin, Germany

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Phase 1

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Normal Saline
Drug: CDX-0159

First Posted Date: 2020-09-04

Last Posted Date: 2023-07-19

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 45

Registration Number: NCT04538794

Locations: 🇺🇸
ForCare Clinical Research, Tampa, Florida, United States
🇺🇸
Dawes Fretzin Clinical Research, Indianapolis, Indiana, United States
🇺🇸
Arizona Allergy & Immunology Research, Gilbert, Arizona, United States

and more 11 locations

A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer
Cholangiocarcinoma
MSI-H Colorectal Cancer
Esophageal Cancer
Fallopian Tube Cancer
Renal Cell Carcinoma
Primary Peritoneal Carcinoma
Breast Cancer
Gastric Cancer
Ovarian Cancer

Interventions: Drug: CDX-527

First Posted Date: 2020-06-22

Last Posted Date: 2023-06-18

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 27

Registration Number: NCT04440943

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Duke Cancer Center, Durham, North Carolina, United States
🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

and more 2 locations

A Phase 1 Study of CDX-0159

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Normal saline
Drug: CDX-0159

First Posted Date: 2019-10-31

Last Posted Date: 2020-07-07

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 32

Registration Number: NCT04146129

Locations: 🇺🇸
Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Breast Cancer
Gastric Cancer
Fallopian Tube Cancer
Other Solid Tumors
Indolent B-cell Lymphomas
Waldenstrom's Disease
Marginal Zone Lymphoma
Pancreatic Adenocarcinoma
Esophageal Cancer
Primary Peritoneal Cancer

Interventions: Drug: CDX-1140
Drug: CDX-301
Drug: Chemotherapy
Drug: pembrolizumab

First Posted Date: 2017-11-06

Last Posted Date: 2024-03-28

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 132

Registration Number: NCT03329950

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Houston Methodist, Houston, Texas, United States
🇺🇸
Northside Hospital, Inc., Atlanta, Georgia, United States

and more 8 locations

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Phase 2

Terminated

Conditions: Advanced Head and Neck Squamous Cell Carcinoma

Interventions: Drug: CDX-3379 and cetuximab

First Posted Date: 2017-08-21

Last Posted Date: 2023-04-03

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 30

Registration Number: NCT03254927

Locations: 🇺🇸
University of Pennsylvania Hospital, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 7 locations

Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut

Conditions: Recurrent GBM

First Posted Date: 2017-03-03

Last Posted Date: 2017-10-18

Lead Sponsor: Celldex Therapeutics

Registration Number: NCT03068650

Individual Patient Expanded Access-Glembatumumab Vedotin

Conditions: Metastatic gpNMB Expressing Triple Negative Breast Cancer

First Posted Date: 2017-03-01

Last Posted Date: 2018-05-21

Lead Sponsor: Celldex Therapeutics

Registration Number: NCT03067935

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

Phase 1

Terminated

Conditions: Kidney Neoplasms
Renal Cell Carcinoma (RCC)
Clear-cell Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Ovarian Clear Cell Carcinoma

Interventions: Drug: CDX-014

First Posted Date: 2016-07-20

Last Posted Date: 2020-06-04

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 16

Registration Number: NCT02837991

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy